Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics reports news on its CNS oncology business, which combines precision diagnostics with targeted radiopharmaceutical development for central nervous system cancers. Recurring updates cover REYOBIQ™ (rhenium Re186 obisbemeda), a radiotherapeutic program for indications including leptomeningeal metastases and recurrent glioblastoma, as well as clinical and translational presentations, regulatory designations, manufacturing technology transfer and supply-chain partnerships.
The company’s news also covers the commercial expansion of CNSide®, including payer coverage, Medicare enrollment and reimbursement work for its cerebrospinal fluid assay platform. Corporate updates include leadership appointments, equity inducement grants under Nasdaq rules, financial results, capital actions and listing-compliance matters tied to its Nasdaq-traded common stock.
Plus Therapeutics (Nasdaq:PSTV) signed a strategic partnership with Ephemeral Technologies to deploy an AI-native platform for CNS oncology. The platform will integrate Plus’ therapeutic, diagnostic, and bioinformatics data to derive actionable intelligence and support precision neuro-oncology initiatives and operational workflows from 2026 onward.
Plus Therapeutics (Nasdaq:PSTV) reported Q1 2026 results and key milestones for its REYOBIQ clinical program and CNSide commercial rollout.
Q1 revenue was $1.0M, operating loss $7.1M, net loss $6.9M ($1.05/share), and cash/investments $15.1M after a $15M upsized offering.
Highlights include FDA Orphan Drug Designation for REYOBIQ in pediatric malignant gliomas, a Category III CPT code for REYOBIQ delivery, expanded CNSide payer coverage to about 81M lives, Medicare enrollment and a unique PLA code for CNSide, and a second GMP manufacturing site for REYOBIQ. The company reaffirmed 2026 milestones for Phase 2/Phase 1 trials, commercial manufacturing scale-up, and CNSide test and coverage targets.
Plus Therapeutics (NASDAQ: PSTV) reported an oral plenary presentation at AANS (May 1-4, 2026) reviewing clinical and translational data for REYOBIQ (rhenium Re186 obisbemeda) in leptomeningeal metastases (LM).
Key points: Phase 1 ReSPECT-LM showed median overall survival ~9 months at the recommended Phase 2 dose versus historical ~2–6 months; robust circulating tumor cell reductions; favorable safety; target-to-off-target dose ratio >100:1. A multiple-dose Phase 1 trial is currently enrolling at UT Health San Antonio.
Plus Therapeutics (Nasdaq: PSTV) announced that subsidiary CNSide Diagnostics is enrolled in Medicare and received a Provider Transaction Access Number (PTAN), establishing the lab as Medicare‑enrolled for the CNSide® CSF Assay Platform including the tumor cell enumeration (TCE) test. Claims will be reimbursed if deemed reasonable and necessary by the local Medicare Administrative Contractor.
The company cited a pathway to ~35 million Medicare Advantage beneficiaries, existing ~81 million commercial covered lives, and a target of 150 million+ covered lives in 2026. A new CPT code 0640U is effective for billing July 1, 2026, with pricing via crosswalk or gapfill.
Plus Therapeutics (Nasdaq: PSTV) announced that Blue Shield of California will provide reimbursement for the CNSide® CSF Tumor Cell Enumeration assay, effective April 2026, expanding covered lives from ~75 million to ~81 million (+6 million).
The coverage aims to reduce reimbursement barriers, accelerate adoption across oncology centers, and advance the company’s 2026 objective of 150 million covered lives. CNSide reports >11,000 tests since 2020, sensitivity 92%, specificity 95%, and treatment decisions influenced in 90% of cases. Health economic analyses cited ~40% reduction in leptomeningeal metastases-related costs.
Plus Therapeutics (Nasdaq: PSTV) began manufacturing activities and technology transfer with SpectronRx under a Master Services Agreement to support GMP late-stage clinical supply of REYOBIQ and Rhenium-186.
The agreement adds SpectronRx as a second GMP site, centralizes isotope processing and drug manufacture in one Indiana facility, and aims to advance manufacturing scale-up toward a 2026 target milestone for late-stage clinical supply.
Plus Therapeutics (Nasdaq: PSTV) granted inducement equity awards to Eric J Daniels, M.D., who joined as Chief Development Officer on April 20, 2026. The awards include 20,000 stock options and 20,000 restricted stock units (RSUs), approved under Nasdaq Rule 5635(c)(4).
Options have a 10-year term with an exercise price of $7.30 (fair market value at grant). Options vest over four years; RSUs vest over three years, each subject to continued service.
Plus Therapeutics (Nasdaq: PSTV) announced it has regained compliance with Nasdaq's minimum bid price rule. Nasdaq confirmed the company's closing bid price was at or above $1.00 per share for 10 consecutive business days from April 6, 2026 to April 17, 2026.
Nasdaq advised the matter is closed, restoring full compliance with Listing Rule 5550(a)(2).
Plus Therapeutics (Nasdaq: PSTV) appointed Randy H. Goodman, PhD, MHA, as Vice President, Value Strategy & HEOR, effective April 13, 2026. Dr. Goodman brings 20+ years of payer strategy, HEOR, and policy experience to support CNSide adoption and commercialization of REYOBIQ.
The company granted inducement equity: 4,500 options (10-year term, $5.41 exercise) and 4,500 RSUs, with standard multi-year vesting schedules approved under Nasdaq Rule 5635(c)(4).
Plus Therapeutics (Nasdaq: PSTV) appointed Eric J. Daniels, M.D., MBA as Chief Development Officer, effective April 20, 2026. Dr. Daniels brings more than two decades of clinical development, regulatory strategy, and corporate operations experience to advance REYOBIQ and the company’s CNS-focused radiopharmaceutical pipeline.
The hire follows senior roles including CDO at Kiora Pharmaceuticals, co-founder of Bayon Therapeutics, and CEO of OccuRx, and is positioned to strengthen Plus’s development execution as it advances clinical programs.